Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313373356> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4313373356 endingPage "167.2" @default.
- W4313373356 startingPage "167.2" @default.
- W4313373356 abstract "Abstract Soluble CD40L and agonistic anti-CD40 monoclonal antibody are adjuvants used in vaccination settings. Vaccines based on anti-CD40 antibodies fused to HIV-1 antigens are in clinical development. Studies with current anti-CD40-based dendritic cell (DC) targeting vaccines show that co-administration of an adjuvant is needed for maximal immune responses. We show that by fusing CD40L to CD40-targeting antibodies, activation of DCs concomitant with antigen uptake and processing is maximized, and this provides a context CD40-targeting vaccines with intrinsic adjuvant activity. Direct fusion of CD40L to L or H chain C-termini results in CD40 agonists with ‘superagonist’ properties. Especially on DCs, both potency and efficacy for induction of cytokine secretion and activation markers is greatly enhanced compared to known strong agonists like Pfizer’s anti-CD40 CP-870-89 antibody. This potency was maintained by anti-CD40-CD40L constructs fused to HIV-1 antigens from Gag, Nef, and Pol regions (HIV5pep). Anti-CD40-CD40L-HIV5pep preferentially expanded CD8+ T cells from HIV-1+ donor PBMCs compared to the same antibody-antigen fusions without attached CD40L. Anti-CD40-CD40L-TEα and anti-CD40-TEα both evoked robust proliferation of TEα-specific CD4+ T cells in human CD40 transgenic mice, but only anti-CD40-CD40L-TEα vaccine elicited TEα-specific CD4+ T cells producing IFNγ. Also, anti-CD40-CD40L-Env gp140 vaccine without adjuvant in human CD40 transgenic mice elicited stronger anti-Env gp140 antibody responses than anti-CD40-Env gp140 vaccine. Thus superagonist anti-CD40 antibodies directly fused to the natural ligand show great advantage in inducing immune responses without the use of an extrinsic adjuvant." @default.
- W4313373356 created "2023-01-06" @default.
- W4313373356 creator A5003608094 @default.
- W4313373356 creator A5005368354 @default.
- W4313373356 creator A5007790779 @default.
- W4313373356 creator A5027947171 @default.
- W4313373356 creator A5037268042 @default.
- W4313373356 creator A5040599648 @default.
- W4313373356 creator A5041266693 @default.
- W4313373356 creator A5041345629 @default.
- W4313373356 creator A5046861195 @default.
- W4313373356 creator A5087237101 @default.
- W4313373356 date "2020-05-01" @default.
- W4313373356 modified "2023-10-17" @default.
- W4313373356 title "Dendritic cell targeting anti-CD40 antibody-CD40L-HIV-1 vaccines are adjuvant intrinsic" @default.
- W4313373356 doi "https://doi.org/10.4049/jimmunol.204.supp.167.2" @default.
- W4313373356 hasPublicationYear "2020" @default.
- W4313373356 type Work @default.
- W4313373356 citedByCount "0" @default.
- W4313373356 crossrefType "journal-article" @default.
- W4313373356 hasAuthorship W4313373356A5003608094 @default.
- W4313373356 hasAuthorship W4313373356A5005368354 @default.
- W4313373356 hasAuthorship W4313373356A5007790779 @default.
- W4313373356 hasAuthorship W4313373356A5027947171 @default.
- W4313373356 hasAuthorship W4313373356A5037268042 @default.
- W4313373356 hasAuthorship W4313373356A5040599648 @default.
- W4313373356 hasAuthorship W4313373356A5041266693 @default.
- W4313373356 hasAuthorship W4313373356A5041345629 @default.
- W4313373356 hasAuthorship W4313373356A5046861195 @default.
- W4313373356 hasAuthorship W4313373356A5087237101 @default.
- W4313373356 hasConcept C147483822 @default.
- W4313373356 hasConcept C154317977 @default.
- W4313373356 hasConcept C159047783 @default.
- W4313373356 hasConcept C159654299 @default.
- W4313373356 hasConcept C202751555 @default.
- W4313373356 hasConcept C203014093 @default.
- W4313373356 hasConcept C2777863537 @default.
- W4313373356 hasConcept C2778170410 @default.
- W4313373356 hasConcept C39347974 @default.
- W4313373356 hasConcept C542903549 @default.
- W4313373356 hasConcept C55493867 @default.
- W4313373356 hasConcept C86803240 @default.
- W4313373356 hasConcept C8891405 @default.
- W4313373356 hasConceptScore W4313373356C147483822 @default.
- W4313373356 hasConceptScore W4313373356C154317977 @default.
- W4313373356 hasConceptScore W4313373356C159047783 @default.
- W4313373356 hasConceptScore W4313373356C159654299 @default.
- W4313373356 hasConceptScore W4313373356C202751555 @default.
- W4313373356 hasConceptScore W4313373356C203014093 @default.
- W4313373356 hasConceptScore W4313373356C2777863537 @default.
- W4313373356 hasConceptScore W4313373356C2778170410 @default.
- W4313373356 hasConceptScore W4313373356C39347974 @default.
- W4313373356 hasConceptScore W4313373356C542903549 @default.
- W4313373356 hasConceptScore W4313373356C55493867 @default.
- W4313373356 hasConceptScore W4313373356C86803240 @default.
- W4313373356 hasConceptScore W4313373356C8891405 @default.
- W4313373356 hasIssue "1_Supplement" @default.
- W4313373356 hasLocation W43133733561 @default.
- W4313373356 hasOpenAccess W4313373356 @default.
- W4313373356 hasPrimaryLocation W43133733561 @default.
- W4313373356 hasRelatedWork W1542522870 @default.
- W4313373356 hasRelatedWork W1969138142 @default.
- W4313373356 hasRelatedWork W2027670370 @default.
- W4313373356 hasRelatedWork W2034076496 @default.
- W4313373356 hasRelatedWork W2098907034 @default.
- W4313373356 hasRelatedWork W2386116568 @default.
- W4313373356 hasRelatedWork W2389962403 @default.
- W4313373356 hasRelatedWork W2947566581 @default.
- W4313373356 hasRelatedWork W3030040176 @default.
- W4313373356 hasRelatedWork W4313347863 @default.
- W4313373356 hasVolume "204" @default.
- W4313373356 isParatext "false" @default.
- W4313373356 isRetracted "false" @default.
- W4313373356 workType "article" @default.